Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sofpironium Bromide Gel 15% in Axillary Hyperhidrosis
NCT03836287Phase 3Completed
- Sponsor
- Botanix Pharmaceuticals
- Start
- Oct 2020
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in primary axillary hyperhidrosis (PAH) comparing Sofpironium Bromide with Vehicle (2 arms). Primary endpoints: Proportion of Participants with >=2-point Improvement in Hyperhidrosis Disease Severity Measure-Axillary-7 Item Total Score at 6 weeks and Change in Rank Gravimetric Sweat Production at 6 weeks. Started Oct 2020; status: completed.
02
Drugs
sofpironium
03
Conditions
primary axillary hyperhidrosis (PAH)
Beyond the preview
Go deeper on NCT03836287.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03836287.